NDA 211192 · Servier
Tibsovo
Ivosidenib · Oral · Isocitrate Dehydrogenase 1 Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 20, 2018
Approved uses
5
Original approval plus efficacy supplements
Registered trials
66
13 Phase 3, 28 recruiting
FAERS reports
2,178
1,366 serious, 229 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME IN AML AND MDS Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DIFFERENTIATION SYNDROME IN AML AND MDS See full prescribing information for complete boxed warning. Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution ( 5.1 ,...
What it is approved for
From the label in effect Dec 22, 2025.
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ). 1.1 Newly Diagnosed Acute Myeloid Leukemia TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14.1) ]. 1.2 Relapsed or Refractory Acute Myeloid Leukemia TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14.2) ] . 1.3 Relapsed or Refractory Myelodysplastic Syndromes TIBSOVO is indicated for the treatment of adult...
Mechanism: Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of ivosidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations in patients with AML are R132H and R132C...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 24, 2023 Supplement 11 · Efficacy · priority review Breakthrough therapyOrphanLabelMedication GuideLetter
- May 25, 2022 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Aug 25, 2021 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- May 2, 2019 Supplement 1 · Efficacy · priority review LabelLetter
- Jul 20, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- TIBSOVO · IVOSIDENIB 250MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivosidenib" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerPivotal-lookingNot yet recruiting
UNICANCERAcademic, hospital or other
NCT07745296 · 990 participants (planned) · Start Jan 2, 2027 · Primary completion Jul 2, 2033
Drug: Futibatinib; Ivosidenib + Capecitabine and 2 more · For: Biliary Tract Cancer (BTC)
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyPivotal-lookingActive, not recruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT03839771 · 968 participants (planned) · Start Mar 1, 2019 · Primary completion Apr 17, 2027
Drug: AG-120; Placebo for AG-120 and 2 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Sites: Adelaide, Australia; Brisbane, Australia; Camperdown, Australia · 181 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
- MRD-positive AML Clinical StudyPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07131059 · 537 participants (planned) · Start May 11, 2024 · Primary completion May 10, 2028
Drug: Ivosidenib; Gilteritinib and 10 more · For: AML, Adult
Sites: Tianjin, China
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SitePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498521 · 529 participants · Start Jul 10, 2018 · Primary completion Feb 14, 2023
Drug: Alectinib; Vismodegib and 16 more · For: Cancer of Unknown Primary Site
Sites: Blacktown, Australia; St Leonards, Australia; South Brisbane, Australia · 125 sites in all
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06265545 · 458 participants (planned) · Start Feb 22, 2024 · Primary completion Jan 30, 2028
Drug: Ivosidenib; Venetoclax and 7 more · For: AML; Refractory; Relapsed
Sites: Tianjin, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use656
- fatigue171
- nausea124
- diarrhoea123
- differentiation syndrome100
- malignant neoplasm progression89
- disease progression88
- product use issue88
- febrile neutropenia87
- drug ineffective83
- electrocardiogram qt prolonged78
- neutropenia76
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 4 |
| 2018 | 23 |
| 2019 | 236 |
| 2020 | 431 |
| 2021 | 398 |
| 2022 | 99 |
| 2023 | 176 |
| 2024 | 175 |
| 2025 | 290 |
| 2026 | 346 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tibsovo (IVosidenib)
2024 spending
$265M
Beneficiaries
1,503
8,705 claims
Per beneficiary
$176,470
$536.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $110,060,482 |
| 2023 | $184,193,061 |
| 2024 | $265,234,785 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
Montesinos P, Recher C, Vives S, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
Montesinos P, Marchione DM, Recher C, et al. · Blood Adv 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX, Macarulla T, Javle MM, et al. · JAMA Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, et al. · N Engl J Med 2018 · Clinical Trial, Phase I, Multicenter Study
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Mellinghoff IK, Lu M, Wen PY, et al. · Nat Med 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Servier
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.